CTLA4 and acute myeloid leukemia: The expression of CTLA-4, PD-1, and LAG3 in the IPM-HR group was significantly higher than that in the IPM-LR group in non-M3 AML patients in TCGA cohort (P = 0.010, 0.039, and < 0.0001, Fig. 4c).